An open-label, multicenter Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of XNW21015 in subjects with advanced solid tumors
Latest Information Update: 06 Aug 2024
At a glance
- Drugs XNW 21015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2024 New trial record